Prosecution Insights
Prosecution Insights
13 pending office actions • 8 clients • 13 examiners • 10 art units • 0 of 13 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 13 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 13 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 3 (23%) |
| §102 only | 1 (8%) |
| §112 only | 1 (8%) |
| Double-patenting + other | 1 (8%) |
| No statute on record | 7 (54%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KUCKLA, ANNA GRACE | 1 | 51.3% | +52.1% |
| HERNANDEZ, JACKSON J | 1 | 52.8% | +51.5% |
| HOWELL, THEODORE R | 1 | 66.8% | +25.4% |
| MOU, LIYUAN | 1 | 43.2% | +58.1% |
| HILL, MYRON G | 1 | 66.5% | +19.8% |
| CHANDRA, GYAN | 1 | 71.1% | +27.7% |
| NOTTINGHAM, KYLE GREGORY | 1 | 60.8% | +33.8% |
| WHITE, DAWANNA SHAR-DAY | 1 | 62.3% | +24.5% |
| BURKETT, DANIEL JOHN | 1 | 65.4% | +24.5% |
| CHONG, YONG SOO | 1 | 43.7% | +41.6% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18113887 | THERAPEUTIC DRUG FOR MOTOR COMPLICATIONS IN PARKINSON'S DISEASE | NOTTINGHAM, KYLE GREGORY | 119d overdue |
| 18235753 | BENZAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | HERNANDEZ, JACKSON J | 77d overdue |
| 18201885 | CYP46A1 INHIBITORS AND METHODS OF USE THEREOF | MOU, LIYUAN | 10d overdue |
| 18015445 | POLYMORPHS OF A GABAA ALPHA5 AGONIST AND METHODS OF USING IN THE TREATMENT OF COGNITIVE IMPAIRMENT | BURKETT, DANIEL JOHN | 8d overdue |
| 18029806 | METHODS OF DETECTING ANTI-AAV ANTIBODIES | HILL, MYRON G | 14d |
| 18015439 | COMBINATIONS OF GABAA ALPHA 5 AGONISTS AND SV2A INHIBITORS AND METHODS OF USING IN THE TREATMENT OF COGNITIVE IMPAIRMENT | WHITE, DAWANNA SHAR-DAY | 14d |
| 17786175 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | CHONG, YONG SOO | 19d |
| 18411753 | METHODS FOR PREVENTING OR SLOWING THE PROGRESSION OF COGNITIVE DECLINE OR IMPAIRMENT IN SUBJECTS | KUCKLA, ANNA GRACE | 35d |
| Client (Assignee) | Pending OAs |
|---|---|
| AGENEBIO, INC. | 5 |
| SAGE THERAPEUTICS, INC. | 2 |
| Johns Hopkins | 1 |
| Sangamo Therapeutics, Inc. | 1 |
| Restore Vision Inc. | 1 |
| Sumitomo | 1 |
| Atsuo Ochi | 1 |
| LadRx | 1 |
| Art Unit | Apps |
|---|---|
| 1628 | 3 |
| 1627 | 2 |
| 1626 | 1 |
| 1671 | 1 |
| 1674 | 1 |
| 1621 | 1 |
| 1624 | 1 |
| 1623 | 1 |
| 1633 | 1 |
| 1618 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18411753 | METHODS FOR PREVENTING OR SLOWING THE PROGRESSION OF COGNITIVE DECLINE OR IMPAIRMENT IN SUBJECTS | The Johns Hopkins University | KUCKLA, ANNA GRACE | 1626 | Other | Non-Final OA | 35d | Pending | Jan 12, 2024 |
| 18235753 | BENZAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | Agenebio, Inc. | HERNANDEZ, JACKSON J | 1627 | Other | Non-Final OA | 77d overdue | Pending | Aug 18, 2023 |
| 18216057 | OXYSTEROLS AND METHODS OF USE THEREOF | Sage Therapeutics, Inc. | HOWELL, THEODORE R | 1628 | Other | Final Rejection | 39d | Pending | Jun 29, 2023 |
| 18201885 | CYP46A1 INHIBITORS AND METHODS OF USE THEREOF | Sage Therapeutics, Inc. | MOU, LIYUAN | 1628 | Other | Non-Final OA | 10d overdue | Pending | May 25, 2023 |
| 18029806 | METHODS OF DETECTING ANTI-AAV ANTIBODIES | Sangamo Therapeutics, Inc. | HILL, MYRON G | 1671 | §103 | Non-Final OA | 14d | Pending | Mar 31, 2023 |
| 18026964 | COMPOSITION FOR TREATING OR PREVENTING DISEASES, DISORDERS, OR CONDITIONS ASSOCIATED WITH ENDOPLASMIC RETICULUM STRESS OR ALL-TRANS-RETINAL, PROTECTING RETINAL THICKNESS, OR SUPPRESSING REDUCTION IN RETINAL THICKNESS OR PROGRESS OF REDUCTION IN RETINAL THICKNESS | Restore Vision Inc. | CHANDRA, GYAN | 1674 | DPOther | Non-Final OA | 60d | Pending | Mar 17, 2023 |
| 18113887 | THERAPEUTIC DRUG FOR MOTOR COMPLICATIONS IN PARKINSON'S DISEASE | Sumitomo Pharma Co., Ltd. | NOTTINGHAM, KYLE GREGORY | 1621 | Other | Non-Final OA | 119d overdue | Pending | Feb 24, 2023 |
| 18015439 | COMBINATIONS OF GABAA ALPHA 5 AGONISTS AND SV2A INHIBITORS AND METHODS OF USING IN THE TREATMENT OF COGNITIVE IMPAIRMENT | Agenebio, Inc. | WHITE, DAWANNA SHAR-DAY | 1627 | Other | Non-Final OA | 14d | Pending | Jan 10, 2023 |
| 18015445 | POLYMORPHS OF A GABAA ALPHA5 AGONIST AND METHODS OF USING IN THE TREATMENT OF COGNITIVE IMPAIRMENT | Agenebio, Inc. | BURKETT, DANIEL JOHN | 1624 | §103 | Non-Final OA | 8d overdue | Pending | Jan 10, 2023 |
| 17786175 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | Agenebio, Inc. | CHONG, YONG SOO | 1623 | §102 | Non-Final OA | 19d | Pending | Jun 16, 2022 |
| 17775801 | METHODS AND A KIT TO REPROGRAM SOMATIC CELLS | Atsuo Ochi | RAHMAN, MASUDUR | 1633 | §112 | Non-Final OA | 97d overdue | Pending | May 10, 2022 |
| 17372405 | COMBINATIONS OF GABAA ALPHA 5 AGONISTS AND SV2A INHIBITORS AND METHODS OF USING IN THE TREATMENT OF COGNITIVE IMPAIRMENT | Agenebio, Inc. | BARSKY, JARED | 1628 | Other | Final Rejection | 56d | Pending | Jul 09, 2021 |
| 17262133 | IMAGING AGENTS FOR RADIOLABELING EXOGENOUS AND ENDOGENOUS ALBUMIN | Ladrx Corporation | SCHLIENTZ, LEAH H | 1618 | §103 | Final Rejection | 35d overdue | Pending | Jan 21, 2021 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial